PAREXEL International Corporation (PRXL) has risen sharply, recording gains of 6.44% in the past 4 weeks. However, the stock has corrected -0.24% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 6.04% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
PAREXEL International Corporation is up 16.6% in the last 3-month period. Year-to-Date the stock performance stands at 1.86%. The stock has recorded a 20-day Moving Average of 2.37% and the 50-Day Moving Average is 7.84%.
PAREXEL International Corporation (NASDAQ:PRXL): The stock opened at $69.11 on Friday but the bulls could not build on the opening and the stock topped out at $69.98 for the day. The stock traded down to $68.96 during the day, due to lack of any buying support eventually closed down at $69.39 with a loss of -0.06% for the day. The stock had closed at $69.43 on the previous day. The total traded volume was 267,785 shares.
Also, Citigroup maintains its view on PAREXEL International Corporation (NASDAQ:PRXL) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Citigroup raises the price target from $74 per share to $80 per share on PAREXEL International Corporation. The rating by the firm was issued on August 5, 2016.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management, data management, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, medical imaging services, electronic data capture systems, clinical trial management systems, Web-based portals, and other product development tools and services.